Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;51(7):1982-90.
doi: 10.1194/jlr.M005348. Epub 2010 Mar 8.

Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease

Affiliations

Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease

Jan A Krikken et al. J Lipid Res. 2010 Jul.

Abstract

Animal experiments show that the kidney contributes to apolipoprotein (apo)A-I catabolism. We tested relationships of HDL cholesterol (HDL-C) and apo-I with kidney function in subjects without severe chronic kidney disease. Included was a random sample of the general population (part of the PREVEND cohort). Kidney function [estimated glomerular filtration rate (e-GFR) by two well-established equations and creatinine clearance], HDL-C, triglycerides, apoA-I and insulin resistance (HOMAir) were measured in 2,484 fasting subjects (e-GFR>or=45 ml/min/1.73 m2) without macroalbuminuria, cardiovascular disease, diabetes, or the use of anti-hypertensives and/or lipid-lowering agents. HDL-C (r=-0.056 to -0.102, P<0.01 to <0.001) and apo A-I (r=-0.096 to -0.126, P<0.001) were correlated inversely with both GFR estimates and creatinine clearance in univariate analyses. Multiple linear regression analyses also demonstrated inverse relationships of HDL-C and apoA-I with all measures of kidney function even after adjustment for age, sex, waist circumference, HOMAir, triglycerides, and urinary albumin excretion (P=0.053 to 0.004). In conclusion, HDL-C and apoA-I are inversely related to e-GFR and creatinine clearance in subjects without severely compromised kidney function, which fits the concept that the kidney contributes to apoA-I regulation in humans. High glomerular filtration rate may be an independent determinant of a pro-atherogenic lipoprotein profile.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Continuous relationships of HDL-C, apoA-I, and apoA-II with e-GFR, calculated with the MDRD formula, analyzed by polynomial regression analysis. (upper, middle, and lower panel, respectively). Lines of best fit (polynomial quadratic) with 95% confidence intervals are shown.
Fig. 2.
Fig. 2.
HDL-C, apoA-I, and apoA-II (upper, middle, and lower panel respectively) according to quintiles of eGFR estimated by the MDRD-equation. Ranges of e-GFR in the increasing quintiles were: 47–70, 70–77, 77–84, 84–92 and 92–148 ml/min/1.73 m2, respectively. HDL-C and apoA-I: * P for trend < 0.001 by one-way ANOVA. ApoA-II, P = 0.83.

Similar articles

Cited by

References

    1. Vega G. L., Grundy S. M. 1996. Hypoalphalipoproteinemia (low high density lipoprotein cholesterol) as a risk factor for coronary heart disease. Curr. Opin. Lipidol. 7: 209–216. - PubMed
    1. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., Qizilbash N., Peto P., Collins R. 2007. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 207: 1829–1839. - PubMed
    1. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. 2002. Circulation. 106: 3143–3421. - PubMed
    1. Borggreve S. E., de Vries R., Dullaart R. P. F. 2003. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33: 1051–1069. - PubMed
    1. Linsel-Nitschke P., Tall A. R. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4: 193–205. - PubMed

Publication types